NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
3
Data completeness
2/8 — Basic
CHLOR-TRIMETON (chlorpheniramine maleate) by Merck & Co.. Approved for covid-19, allergic rhinitis.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOR-TRIMETON (chlorpheniramine maleate) is a first-generation H1-receptor antagonist antihistamine in injectable form currently in pre-launch development by Merck & Co. It is indicated for allergic rhinitis and COVID-19, though the injectable formulation represents a novel delivery approach for this established active pharmaceutical ingredient.
Pre-Launch
Pre-launch status indicates active commercial team buildout focused on market preparation and regulatory readiness; limited historical spending data suggests new market segment entry for Merck's antihistamine portfolio.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHLOR-TRIMETON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.